Background. mRNA deadenylation (shortening of the poly (A) tail) is often triggered
Introduction.
The post-transcriptional regulation of mRNAs in the cytoplasm is an important process implicated in controlling the dynamic changes in the expression of a number of regulatory proteins. Furthermore, in the early embryos of many, if not all, metazoans, gene transcription is essentially silent and the post-transcriptional controls exerted on the inherited maternal mRNAs are of paramount importance for the ensuing development. The post-transcriptional regulation affecting maternal mRNAs has been largely studied in Xenopus (Xenopus laevis) early embryos that are particularly suited to these studies due to their large size and availability. Studies in a number of laboratories have shown that the translation of maternal mRNAs is tightly correlated with the adenylation status; mRNAs that are polyadenylated are in general recruited into polysomes and translated whereas deadenylated mRNAs are released from polysomes (reviewed in . In the large majority of cases in eukaryotes, deadenylation (shortening of the poly (A) tail) is the rate-limiting event of mRNA degradation. In Xenopus embryos, this is not the case as mRNA degradation does not immediately follow deadenylation. Although deadenylated mRNAs are not translated, they are stable until the blastula stage, several hours after fertilization (Audic et al., 1997; Voeltz and Steitz, 1998) . Therefore, mRNA deadenylation and degradation, although causally coupled, are temporally separated.
Targeting of a mRNA for deadenylation is generally achieved via specific cis sequence element(s) that reside within mRNA 3' untranslated regions (3'UTR). These cis elements bind specific proteins that in turn influence mRNA deadenylation. The rapid deadenylation of unstable mRNAs such as those encoding mammalian cytokines or proto-oncogenes is mediated by AU-rich elements (AREs) that have been divided into three classes, depending on the presence and the distribution of the core motif AUUUA (Chen and Shyu, 1995) . A number of ARE-binding proteins have been characterized, and a role, either stimulatory or inhibitory, in mRNA deadenylation established for some of them (for a recent review see Barreau et al., 2005) .
We have shown previously that a sequence termed EDEN (Embryo Deadenylation ElemeNt), and an associated RNA-binding protein (EDEN-BP) are responsible for the deadenylation of a subclass of mRNAs after fertilization of The final Version of Record is available at www.biolcell.org extracts abolishes EDEN-dependent deadenylation activity (Paillard et al., 1998) , that is restored by the addition of recombinant protein . When EDEN-BP was depleted in developing embryos by the injection of specific antibodies or morpholino antisense oligonucleotides, an important disruption of somite segmentation was observed (Gautier-Courteille et al., 2004) . Interestingly, a reporter RNA containing human c-jun ARE, a "class III" (non-AUUUA containing) ARE (Chen and Shyu, 1995) , is rapidly deadenylated after injection in Xenopus embryos. This deadenylation is also abrogated by immunoneutralizing EDEN-BP, demonstrating that it depends on active EDEN-BP (Paillard et al., 2002) . This similarity between human c-jun ARE and Xenopus EDEN sequences led us to propose that EDEN sequences define a subgroup of class III AREs (Paillard et al., 2002) . EDEN-BP is one member of the CELF (CUG-binding and Etr3 like factors) family of RNA-binding proteins (for a recent review, Barreau et al., 2006) and human CUG-BP1/CELF1 can act as a deadenylation factor in HeLa cell extracts (Moraes et al., 2006) .
As for most ARE/ARE-binding proteins, the molecular mechanism linking EDEN-BP binding to a RNA and rapid deadenylation remains essentially unknown. A first step toward understanding this mechanism is to identify the partners of EDEN-BP. Here, we have demonstrated using a biochemical assay that EDEN-BP can oligomerize, and we have mapped a domain required for this oligomerization.
Moreover, using deletion mutants and a peptide derived from the interaction domain, we demonstrated the functional importance of EDEN-BP oligomerization for EDEN deadenylation and RNA binding. This is therefore an important step toward understanding the molecular composition of the protein complex that is targeted to mRNAs by the EDEN and is responsible for rapid deadenylation.
RESULTS

Identification of a 27 amino acid domain of EDEN-BP required for oligomerization
We have previously observed that EDEN-BP is able to interact with itself in a yeast two-hybrid assay (Bonnet-Corven et al., 2002) . However, the yeast system can not be taken as a definitive proof that such interactions occur. Therefore, to more The final Version of Record is available at www.biolcell.org clearly demonstrate an EDEN-BP/EDEN-BP interaction, a "GST pull-down" assay was developed. Radiolabelled, untagged EDEN-BP was incubated with GSH beads previously loaded with GST protein, or a fusion of GST with EDEN-BP. The eluate was analyzed by electrophoresis and autoradiography ( Figure 1A) . A significant percentage of the loaded protein was detected in the eluate of the GST-EDEN-BP column (lane 3), as compared with the eluate from the GST column (lane 2). Only a weak signal was detected when the unrelated protein Xenopus Elongation Factor 1 (XEF1 ) was chromatographed on the GST-EDEN-BP column (lane 6), and this signal was not significantly above the background signal obtained after chromatography on the GST column (lane 5).
To ensure that the binding of EDEN-BP to the GST EDEN-BP fusion protein could occur in the context of the embryo, Xenopus eggs were injected with a mRNA encoding a GST-EDEN-BP fusion protein and incubated to allow synthesis of this protein. Undiluted cytoplasmic extracts containing the GST EDEN-BP fusion protein were made from the injected eggs and these extracts were complemented with 35 S labelled EDEN-BP or Firefly luciferase in a minimal amount of rabbit reticulocyte lysate. After incubation with GSH beads, the retained proteins were eluted and analysed by electrophoresis and after transfer to a nitrocellulose membrane. The 35 S labelled proteins were revealed by autoradiography and quantified (Figure 1B, upper panel) . To ensure that equivalent amounts of the fusion protein had been retained on the GSH beads the membrane was then probed with an anti GST antibody ( Figure   1B , lower panel). These analyses showed that the 35 S labelled EDEN-BP was retained on the beads (lane 2) whereas the unrelated 35 S labelled Firefly luciferase was not (lane 6). In these experiments, the 35 S labelled EDEN-BP and the endogenous EDEN-BP can both bind to the GST-EDEN-BP, hence the amount of input radiolabelled protein retained on the beads is less than when only recombinant protein is used as in Figure 1A . Importantly, addition of RNase A to the extract before incubation with the beads did not significantly decrease the amount of labelled EDEN-BP retained by the fusion protein on the GSH beads (in Figure 2B , upper panel, compare lanes 2 and 4).
These data confirm the yeast two-hybrid data that EDEN-BP interacts with itself. Furthermore, they demonstrate that this interaction is not dependent on the presence of RNA. Finally, this interaction is observed both in the context of the embryo cytoplasm and in vitro using proteins expressed in bacteria. We will refer to We next used the GST-pull-down assay to identify the domain of EDEN-BP that is required for oligomerization. In preliminary experiments, fragments of EDEN-BP that were successively shortened from the COOH-terminal extremity were synthesised in reticulocyte lysates and tested for their capacity to be retained on GST-EDEN-BP beads. We observed that a fragment of EDEN-BP covering amino acids 1 to 238 (see Figure 2 for a schematic diagram of EDEN-BP) was efficiently retained on the GST-EDEN-BP, whereas this was not the case for the fragment referred to as pEg7 (Cubizolles et al., 1998) We have previously shown that EDEN-BP provokes the rapid deadenylation of EDEN-containing RNAs (Paillard et al., 1998) . To test if the oligomerization of EDEN-BP is required for deadenylation we used cytoplasmic egg extracts that are proficient for EDEN-dependent deadenylation (Legagneux et al., 1995) and an EDEN-BP immunodepletion/rescue protocol. EDEN-dependent deadenylation is characterised by the appearance of completely deadenylated (A -) transcript containing an EDEN ("EDEN", Gb-Eg2-410 (Legagneux et al., 1995) ) upon incubation in these extracts (see Figure 3 , lanes 1-3). Transcripts devoid of an EDEN or other regulatory sequence elements are also deadenylated in these extracts, albeit much less rapidly, by a "default" process (see the gradual shortening of the "Default" transcript (GbEg2-410A (Legagneux et al., 1995) ). For the default transcript no completely deadenylated molecules are formed even after 3 hours of incubation (see Figure 3 , lanes 1-3). We have previously shown (Paillard et al., 1998) The final Version of Record is available at www.biolcell.org
A 28 amino acids peptide inhibits both oligomerization and EDEN-dependent deadenylation
The above data strongly suggest that the oligomerization of EDEN-BP is required for EDEN-dependent deadenylation. However, the incapacity of mutant EDEN-BP to support EDEN deadenylation could also be an indirect consequence of the deletion of the domain required for oligomerization, for instance if this deletion modified some structural aspects of EDEN-BP. To confirm that oligomerization is required for EDEN deadenylation, we designed another tool to inhibit EDEN-BP oligomerization, namely, a peptide corresponding to the sequence of the amino acids of EDEN-BP required for oligomerization that should compete with full-length EDEN-BP, and thereby inhibit oligomerization by site occupation.
A peptide corresponding to the region 183-210 of EDEN-BP was chemically synthesized. As a control, another peptide, containing the same amino acids as peptide 183-210 but in a different order ("scrambled" peptide) was also synthesized.
The effects of these two peptides on oligomerization were tested in a GST-Pull-Down assay ( Figure 4A ). As above, a strong signal corresponding to EDEN-BP was detected in the eluate of the GST-EDEN-BP beads (0 peptide, lane 2). This signal was reduced about 3 fold when the incubation was performed in the presence of 100 or 400 µM of peptide 183-210 (lanes 3 and 4). In contrast, the same concentration of the Scrambled peptide had no effect on the capacity of the GST-EDEN-BP beads to retain radiolabelled EDEN-BP (lanes 5 and 6).
We next tested the effects of the 183-210 and scrambled peptides on deadenylation in egg extracts. Various concentrations of the scrambled peptide were added to a deadenylation-proficient egg extract, and two test transcripts were incubated in these supplemented extracts ( Figure 4B ). Scrambled peptide concentrations up to 400 µM (upper panel) had no detectable effect on either EDENdependent deadenylation, as measured with the "EDEN" transcript, or on default deadenylation ("Default" transcript). In the same experiment, 400 µM of peptide 183-210 (lower panel, lanes 13-16) almost completely inhibited EDEN-deadenylation, but had no effect on the default deadenylation. 160 or even 64 µM of peptide 183-210 also hampered EDEN-deadenylation though less efficiently and still had no effect on default deadenylation (lanes 5-12). Quantification of these data ( Figure 4C The final Version of Record is available at www.biolcell.org increasing amounts of peptide 183-210 were added. The rate at which the deadenylated transcript accumulated is a direct indication of the deadenylation efficiency (right panel). Comparison of these efficiencies for the various samples confirmed that the Scrambled peptide had no effect on EDEN-dependent deadenylation, whereas this deadenylation was decreased by peptide 183-210 in a dose-dependent manner, reaching 10% of the control with 400µM of peptide.
Therefore, peptide 183-210, but not a scrambled version of this peptide, specifically inhibits EDEN-dependent deadenylation.
Three supplementary controls for the specificity of the peptide 183-210 were made. First, we verified that the effect that was previously observed in cell-free Third, we verified that the inhibitory effect of the peptide 183-210 on EDENdependent deadenylation was observed with substrates other than the Eg2-derived EDEN-containing transcript used in previous figures. Accordingly, two additional transcripts were used, the synthetic globin ORF (Gb ORF, (Audic et al., 1997) ) and this same mRNA containing the c-jun ARE in the 3'UTR (GbORFjun (Paillard et al., 2002) ). The GbORF mRNA is a substrate for default deadenylation whereas the GbORFjun mRNA is deadenylated by the EDEN-dependent process (Audic et al., 1997; Paillard et al., 2002) . As shown in Figure 5 (middle panel) the slow . We have shown above that this peptide has no effect on the slow, default-type deadenylation (see Figure 4B ). We also observed that it did not inhibit the AUUUA-dependent deadenylation, a rapid mechanism in Xenopus embryos that does not require active EDEN-BP (Paillard et al., 2002; Voeltz and Steitz, 1998 ) (data not shown). Hence, peptide 183-210 specifically inhibits the deadenylation of EDEN-containing transcripts in Xenopus embryos or extracts, but not other types of deadenylation.
Oligomerization of EDEN-BP is required for RNA binding
We previously observed that binding of EDEN-BP to the EDEN motif required sequence information proximal to amino acid 320 (Bonnet-Corven et al., 2002) . This suggested to us that RNA binding may require EDEN-BP oligomerization. To test this, an Electrophoretic Mobility Shifts Assay (EMSA) was used. Increasing concentrations of purified recombinant, His-tagged EDEN-BP were incubated with radiolabelled s3'Eg5wt RNA. This RNA was chosen as an EMSA probe since it contains all the necessary sequence information to be a target of the EDENdependent mechanism when injected in Xenopus embryos, but is reasonably short (120 nucleotides) (Paillard et al., 1998) . Two radiolabelled complexes were detected ( Figure 6A ). As the reaction mix only contains purified recombinant EDEN-BP and s3'Eg5wt RNA, they probably correspond to increasing states of oligomerization of EDEN-BP on this target RNA. Based on three independent experiments, the concentration of EDEN-BP required to achieve 50% of bound s3'Eg5wt RNA is 15 +/-5 nM. To verify the specificity of these complexes, the same experiment was reproduced using s3'Eg5C6 as an EMSA probe. This RNA contains a 6 nucleotides mutation (C6) within the EDEN sequence that is sufficient to strongly decrease EDEN-BP binding in UV-cross-linking or affinity chromatography assays (Paillard et al., 1998) . The EMSA pattern obtained with this probe was very different, and a small amount of bound probe was only detected with the highest concentrations of EDEN-BP tested ( Figure 6B) ; the concentration of EDEN-BP required to achieve 50% of binding of this mutant probe is therefore far more than 200 nM. The 28 amino acids EDEN-BP derived peptide that inhibited oligomerization and EDEN-dependent deadenylation also inhibited the binding of EDEN-BP to a substrate RNA, demonstrating that oligomerization is required for RNA binding.
Examples of RNA-binding proteins that are able to oligomerize have been reported, and, in some cases, a reciprocal dependence of oligomerization and RNA binding was analysed. AUF1 was shown to be present as dimers in the absence of RNA.
Upon RNA binding, AUF1 dimers are sequentially recruited to the host RNA, forming tetramers and higher polymers of dimers (Wilson et al., 1999) . U1A is able to homodimerize even in mutants that have lost their capacity to interact with RNA;
however, in the wild-type protein, homodimerization permits cooperative binding (Klein Gunnewiek et al., 2000) . A mutant FMR1 (FMR1 I304N) that is unable to oligomerize can still interact with RNA (Laggerbauer et al., 2001) . In these three (Niessing et al., 2004) . This last situation is evocative of the strong relationship between RNA-binding and oligomerization that we describe here for EDEN-BP.
The Drosophila protein Bruno is closely related to Xenopus EDEN-BP and acts as a translational repressor in oocytes (Castagnetti et al., 2000; Lie and Macdonald, 1999) . Recently, Chekulaeva et al. (2006) showed that in Drosophila oocytes the binding of Bruno to oskar mRNA caused a oligomerisation of the mRNA in a silencing particle. This particle contains Bruno, Cup an eIF4E binding protein and
Me31B that is a homolog of the yeast P-body component and translational repressor
Dhh1P. To our knowledge it has not been determined whether Bruno alone can oligomerize but our data suggests that this may be the case and that the oligomerisation of oskar mRNA is driven by interactions between Bruno monomers.
EDEN-BP is one member of the CELF/Bruno like family of RNA-BPs.
Alignment of the 184 -210 region of EDEN-BP with the corresponding region of the other CELF proteins (Figure 7) showed that this region is highly conserved between the CELF1 (EDEN-BP and CUG-BP1) and CELF2 (ETR-3 and CUG-BP2) proteins.
These two proteins also exhibit the highest degree of overall similarity (see Barreau et al, 2006) . The conservation of this region is less for CELF 3, 4 and 5 and the least for CELF 6. However, it should be noted that a certain number of the amino acid changes are conservative changes (eg K for R at positions 191, 193 and 196; E for D at position 192) . This observation suggests that most if not all of the different CELF proteins are also able to oligomerise and that they could form homo-or heterooligomers depending on the presence or absence of the different CELF proteins in the same cell. This potential flexibility in the RNA binding partner of a CELF protein may be at the base of the large variety of functions described for these proteins (see Barreau et al., 2006) .
Several consequences can be envisaged to result from the oligomerisation of an RNA-BP. First, the binding site of the oligomerized proteins may not match a strict linear "consensus". The sequence could be either direct or an inverted repeat and each individual "motif" could be separated by a variable spacer that could be looped out when the RNA /protein complex formed. Second, the oligomerization could create To produce GST-EDEN-BP in vivo unfertilised Xenopus eggs were injected with 5 ng of in vitro synthesised GST-EDEN-BP mRNA and incubated for 4h at 20°C before making deadenylation proficient (Legagneux et al., 1995) .
Radiolabelled EDEN-BP was produced by in vitro transcription and translation (ProteinScript II, Ambion) in the presence of 35 S-aminoacids using the pT7TS-EDEN-BP plasmid (Paillard et al., 2002) as a matrix. Radiolabelled COOH-shortened fragments of EDEN-BP were produced similarly, but the transcription matrices used were PCR products containing the fragments of EDEN-BP previously described For Electrophoretic Mobility Shift Assays (EMSA), serial dilutions of His-EDEN-BP were made in the following buffer: HEPES 70mM (pH=7.9); KCl 150 mM; EDTA 0.08 mM; MgCl 2 2 mM; DTT 0.2 mM; Glycerol 8%; Yeast tRNA 2µg/µl; Heparin 6.6 µg/µl; BSA 6.6 µg/µl; IGEPAL-CA30 0.06%, and peptide when required.
Radiolabelled probes were made by in vitro transcription with 32 P-UTP and the Promega Riboprobe products using BamH1-linearized s3'Eg5wt and s3'Eg5C6 plasmids (Paillard et al., 1998) . 3 nM of heat-denatured radiolabelled transcript were added to the diluted proteins and incubated for 1h on ice. Complexes were separated by electrophoresis on 5% polyacrylamide gel in 0.5X TBE and 5% glycerol. The dried gels were submitted to Phosphoimager (STORM 840, Molecular Dynamics) analysis.
Quantifications were made using the ImageQuant software (Version 5.4, Molecular Dynamics). The final Version of Record is available at www.biolcell.org
Deadenylation analyses
For deadenylation analyses, capped, polyadenylated, uniformly radiolabelled GbEg2-410, GbEg2-410A, GbORF and GbORFjun transcripts were obtained by in vitro transcription in the presence of 32 P-UTP using the Promega Riboprobe products and the corresponding plasmids (Audic et al., 1997; Legagneux et al., 1995; Paillard et al., 2002) previously linearized with EcoRV. These transcripts were injected, alone or with peptides, into two-cell embryos. Alternatively, RNAs were incubated in 5 µl of deadenylation-proficient activated egg extracts (Legagneux et al., 1995) . In some experiments, these extracts were mock depleted or immunodepleted of EDEN-BP as previously described (Paillard et al., 1998) . Complementation with full-length or mutant EDEN-BP was made by mixing one volume of depleted extract with one volume of programmed wheat germ extract . radiolabelled Gb-Eg2-410 (EDEN) and Gb-Eg2-410A (Default) transcripts (Legagneux et al., 1995) were incubated in these extracts for the indicated times.
RNAs were extracted and the adenylation behaviours of the transcripts were analyzed by denaturing electrophoresis. The radiolabelled RNAs were revealed and RNAs were extracted at the times indicated above each lane and analyzed as above.
Lower panel, A capped, radiolabelled GbORFjun transcript was injected into Xenopus embryos, together with water (lanes 1-3), or 200 ng of peptides 183-210 (lanes 4-6).
RNAs were extracted at the times indicated above each lane and analyzed as above. The final Version of Record is available at www.biolcell.org The final Version of Record is available at www.biolcell.org The final Version of Record is available at www.biolcell.org
